Hyperoside
Specifications
482-36-0CAS Number
207-580-6EC Number
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-oneIUPAC Name
C21H20O12Chemical Formula
464.4 g/molMolecular Weight
Hyperoside; 482-36-0; Hyperin; Hyperosid; Quercetin-3-O-galactoside; Hyperasid; quercetin galactoside; Quercetin 3-O-beta-D-galactopyranoside; Quercetin 3-beta-D-galactopyranoside; 8O1CR18L82; 2-(3,4-Dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; CHEBI:67486; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxychromen-4-one; RefChem:5898; 2-(3,4-dihydroxyphenyl)-3-(alpha-D-galactopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,4R,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxychromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxychromen-4-one; 207-580-6; Quercetin 3-galactoside; Hyperozide; Quercetin-3-galactoside; Quercetin 3-D-galactoside; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; quercetin 3-O-galactoside; MFCD00016933; Jyperin; QUERCETIN 3-B-D-GALACTOSIDE; NSC 407304; CHEMBL251254; Quercetin 3-O-beta-D-galactoside; Quercetin 3-.beta.-D-galactopyranoside; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy-; 2-[3,4-bis(oxidanyl)phenyl]-3-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one; quercetin-3-d-galactoside; UNII-8O1CR18L82; CCRIS 9339; p Hyperin; NSC-407304; Quercetin-3-O-beta-D-galactopyranoside; DTXSID501028789; J6O; Quercetin 3-O-.beta.-D-galactopyranoside; EINECS 207-580-6; Hyperoside (Standard); Quercetin 3-|A-Galactoside; HYPEROSIDE [USP-RS]; BIDD:PXR0057; quercetin-3-O-D-galactoside; MLS000759538; jm5b01461, Compound 84; MEGxp0_000392; orb1224977; orb1304944; orb3140160; quercetin-3-o-galactopyranoside; SCHEMBL1250514; SCHEMBL29509019; SCHEMBL29611459; ACon1_000623; HY-N0452R; quercetin-3-o-beta-d-galactoside; BDBM429266; HMS2051H17; HY-N0452; quercetin-3-beta-D-galactopyranoside; 3-O-beta-D-galacopyranosyl quercetin; BDBM50241367; LMPK12112041; MSK000529; s5453; AKOS015896780; CCG-100970; EBC-457087; MQ08114; NC00220; NCGC00168902-03; AS-56199; SMR000466394; QUERCETIN 3-O-.BETA.-D-GALACTOSIDE; CS-0008982; NS00079301; Quercetin 3-D-galactoside, >=97.0% (HPLC); AB00639910-03; F807988; Hyperoside, primary pharmaceutical reference standard; Q5242815; BRD-K84955386-001-01-1; 3-O-b-D-Galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone; HYPEROSIDE (CONSTITUENT OF ST. JOHN'S WORT) [DSC]; Hyperoside, United States Pharmacopeia (USP) Reference Standard; 2-(3,4-Dihydroxyphenyl)-3-(b-D-galactopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl beta-D-galactopyranoside; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl hexopyranoside #; 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-((2S,4R,5R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one; 2-(3,4-DIHYDROXYPHENYL)-3-(.BETA.-D-GALACTOPYRANOSYLOXY)-5,7-DIHYDROXY-4H-1-BENZOPYRAN-4-ONE; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-; Hyperoside; 3-O-|A-D-galactopy ranosylquercetin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-oneSynonyms